Clinical Trial Update: Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating cabozantinib S-malate with nivolumab, with or without ipilimumab, in patients with metastatic genitourinary tumors; no results reported…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Small Cell Neuroendocrine Carcinoma
• Bladder Squamous Cell Carcinoma
• Bladder Urothelial Carcinoma
• Penile Carcinoma
• Penile Squamous Cell Carcinoma
• Renal Cell Carcinoma
• Renal Pelvis Urothelial Carcinoma
• Ureteral Urothelial Carcinoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING